ANL News
Archived Headlines
- US IPO Weekly Recap: August wraps up with one nano-cap 09/01/23
- US IPO Week Ahead: Quiet August wraps with holdover biotech Adlai Nortye, as big deals prep September IPOs 08/25/23
- US IPO Week Ahead: Holdovers hang around the IPO calendar as pipeline waits for big additions 08/18/23
- US IPO Week Ahead: Handful of deals bring biotech, forestry, and golf clubs to the IPO market 08/11/23
- Cancer biotech Adlai Nortye sets terms for $72 million US IPO 08/10/23
See more
US IPO Weekly Recap: Holdover Adlai Nortye leads 4 IPO week as more small deals enter the pipeline
The third quarter wrapped up with four IPOs and eight pipeline additions. Oncology biotech Adlai Nortye (ANL) raised $58 million at an $849 million market cap. The company originally planned to raise $72 million in August but never priced; it...read more
Cancer biotech Adlai Nortye prices US IPO at $23
Adlai Nortye, a Phase 3 biotech developing immunotherapies for various cancers, raised $58 million by offering 2.5 million ADSs at $23, as expected. A potential investor had indicated on $50 million worth of ADSs in the offering (87% of the deal), and the...read more
Cancer biotech Adlai Nortye sets new terms for $58 million US IPO
Adlai Nortye, a Phase 3 biotech developing immunotherapies for various cancers, announced terms for its IPO on Wednesday. The Cayman Islands-based company plans to raise $58 million by offering 2.5 million ADSs at $23. A potential investor intends to purchase...read more
Cancer biotech Adlai Nortye removes terms, changes underwriters ahead of $72 million US IPO
Adlai Nortye, a Phase 3 biotech developing immunotherapies for various cancers, submitted a blank filing on Tuesday, after setting terms last month to raise $72 million by offering 3 million ADSs at a price range of $22 to $26. In its latest filing, the...read more